409 related articles for article (PubMed ID: 27974549)
1.
Ho DWH; Chan LK; Chiu YT; Xu IMJ; Poon RTP; Cheung TT; Tang CN; Tang VWL; Lo ILO; Lam PWY; Yau DTW; Li MX; Wong CM; Ng IOL
Gut; 2017 Aug; 66(8):1496-1506. PubMed ID: 27974549
[TBL] [Abstract][Full Text] [Related]
2. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.
Luo YD; Fang L; Yu HQ; Zhang J; Lin XT; Liu XY; Wu D; Li GX; Huang D; Zhang YJ; Chen S; Jiang Y; Shuai L; He Y; Zhang LD; Bie P; Xie CM
J Hepatol; 2021 Jan; 74(1):96-108. PubMed ID: 32738450
[TBL] [Abstract][Full Text] [Related]
3. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.
Huynh H; Hao HX; Chan SL; Chen D; Ong R; Soo KC; Pochanard P; Yang D; Ruddy D; Liu M; Derti A; Balak MN; Palmer MR; Wang Y; Lee BH; Sellami D; Zhu AX; Schlegel R; Huang A
Mol Cancer Ther; 2015 May; 14(5):1224-35. PubMed ID: 25724664
[TBL] [Abstract][Full Text] [Related]
4. Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
Dong P; Wang X; Liu L; Tang W; Ma L; Zeng W; Sun S; Zhang L; Zhang N; Shen X; Janssen HLA; Dong L; Zhang S; Chen S
J Hepatol; 2020 Dec; 73(6):1446-1459. PubMed ID: 32610114
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria.
Ye Q; Ling S; Jiang G; Shan Q; Xu S; Zhan Q; Wu Y; Liu Y; Zheng S; Xu X
Eur J Surg Oncol; 2021 Oct; 47(10):2533-2542. PubMed ID: 33902956
[TBL] [Abstract][Full Text] [Related]
7. Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation.
Espinosa M; Roldán-Romero JM; Duran I; de Álava E; Apellaniz-Ruiz M; Cascón A; Garrigos C; Robledo M; Rodriguez-Antona C
BMC Cancer; 2018 May; 18(1):561. PubMed ID: 29764404
[TBL] [Abstract][Full Text] [Related]
8. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
9. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin regulates the proliferation of Huh7, a hepatocellular carcinoma cell line, by up-regulating p53 expression.
Kwon S; Jeon JS; Ahn C; Sung JS; Choi I
Biochem Biophys Res Commun; 2016 Oct; 479(1):74-9. PubMed ID: 27616194
[TBL] [Abstract][Full Text] [Related]
11. Neurogenin 3-directed cre deletion of Tsc1 gene causes pancreatic acinar carcinoma.
Ding L; Han L; Li Y; Zhao J; He P; Zhang W
Neoplasia; 2014 Nov; 16(11):909-17. PubMed ID: 25425965
[TBL] [Abstract][Full Text] [Related]
12. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling.
Liu F; Zhang W; Yang F; Feng T; Zhou M; Yu Y; Yu X; Zhao W; Yi F; Tang W; Lu Y
Sci Rep; 2016 Feb; 6():21260. PubMed ID: 26879559
[TBL] [Abstract][Full Text] [Related]
14. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
15. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.
Menon S; Yecies JL; Zhang HH; Howell JJ; Nicholatos J; Harputlugil E; Bronson RT; Kwiatkowski DJ; Manning BD
Sci Signal; 2012 Mar; 5(217):ra24. PubMed ID: 22457330
[TBL] [Abstract][Full Text] [Related]
16. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
17. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
19. Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.
Kim SH; Kowalski ML; Carson RP; Bridges LR; Ess KC
Dis Model Mech; 2013 Jul; 6(4):925-33. PubMed ID: 23580196
[TBL] [Abstract][Full Text] [Related]
20. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.
Liang MC; Ma J; Chen L; Kozlowski P; Qin W; Li D; Goto J; Shimamura T; Hayes DN; Meyerson M; Kwiatkowski DJ; Wong KK
Oncogene; 2010 Mar; 29(11):1588-97. PubMed ID: 19966866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
